WO1996025932A1 - Medicament preventif et curatif, pour la pneumonie interstitielle, les maladies inflammatoires intestinales ou l'epaississement des vaisseaux, contenant des composes de quinolizinone, des sels de ces composes ou des hydrates - Google Patents
Medicament preventif et curatif, pour la pneumonie interstitielle, les maladies inflammatoires intestinales ou l'epaississement des vaisseaux, contenant des composes de quinolizinone, des sels de ces composes ou des hydrates Download PDFInfo
- Publication number
- WO1996025932A1 WO1996025932A1 PCT/JP1996/000371 JP9600371W WO9625932A1 WO 1996025932 A1 WO1996025932 A1 WO 1996025932A1 JP 9600371 W JP9600371 W JP 9600371W WO 9625932 A1 WO9625932 A1 WO 9625932A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- interstitial pneumonia
- inflammatory bowel
- bowel disease
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
Definitions
- the present invention relates to a prophylactic / therapeutic agent for interstitial pneumonia, inflammatory bowel disease or vascular hyperplasia.
- R 1 is a carboxy group, an amidated carboxy group, a cyano group, a thiocarbamoyl group or a tetrazolyl group
- R 4 is a hydrogen or aryl group
- R 2 is hydrogen, a hydroxy group, a lower alkyl group or a lower alkoxy group
- R 3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkenyloxy,
- Aryl group which may have a suitable substituent which may have a suitable substituent
- An arylthio group, an aryl group, an ar (lower) alkyl group, an arylsulfonyl group, an arylamino group or an aryloxy group which may have a suitable substituent, respectively.
- the present invention relates to a prophylactic / therapeutic agent for interstitial pneumonia, inflammatory bowel disease or vascular hyperplasia, which comprises a quinolizinone compound represented by the formula (1), a salt thereof or a hydrate thereof as an active ingredient. Used in the medical field.
- the quinolizinone compound (I) used in the present invention is known, and is useful as an anti-allergic agent and an anti-inflammatory agent. Furthermore, it is described in Japanese Patent Application Laid-Open No. 6-256187 that it is useful as an antitussive and expectorant.
- this quinolizinone compound (I) is also useful as an analgesic, an anticonjunctivitis agent or an antirheumatic rheumatoid agent (International Publication Number: WO94Z0). 7 4 9 1).
- interstitial pneumonia is the interstitial space of the lung (the space between the alveolar walls bordered by the alveolar epithelial basement membrane), in which the collagen components such as collagen, elastin, and proteoglycan, and the capillaries and This is a general term for a group of pulmonary diseases that have the main site of the lesion in which they surround fibroblasts, etc., and are important for gas exchange.
- interstitial pneumonia In interstitial pneumonia, an increase in inflammatory cells (alveolar macrophages, lymphocytes, neutrophils, acid-resistant cells, etc.) is observed in the alveoli, and so-called alveolitis is present. In this alveolar inflammation, tissue damage is caused by the production and release of inflammatory cells from active inflammatory cells, proteases, and cytotoxic proteins, and the repair function works. Take the process of conversion. In interstitial pneumonia, the line Weihua destroys gas exchange sites and causes respiratory failure.
- Interstitial pneumonia is a disease with a poor prognosis, and there is still no effective prophylactic or therapeutic agent.
- Crohn's disease and ulcerative colitis are intractable chronic inflammatory bowel diseases, and anti-inflammatory antisulfuric agents such as sulfasalazine, etc.
- Immunosuppressants such as zathioprine are used.
- the inventors of the present invention have found that the quinolizinone compound (I), a salt thereof and a hydrate thereof may have an effect of preventing and treating vascular hypertrophy.
- the quinolizinone compound (I), a salt thereof and a hydrate thereof may be used for diseases involving mast cells, such as hepatitis, cirrhosis, ulcerative colitis, renal failure, pulmonary fibrosis, osteoporosis, etc. It is expected to be useful for the treatment of pneumonia, and subsequent research will prevent and treat interstitial pneumonia such as pulmonary fibrosis, and prevent inflammatory bowel diseases such as ulcerative colitis. I found it useful.
- an object of the present invention is to provide a quinolizinone compound (I),
- An object of the present invention is to provide a prophylactic / therapeutic agent for interstitial pneumonia, inflammatory bowel disease or vascular hypertrophy, which contains a salt or a hydrate thereof as an active ingredient.
- “Lower” shall mean from 1 to 6 carbon atoms unless otherwise indicated.
- lower alkyl of the “lower alkyl” and “ar (lower) alkyl” include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary Examples thereof include a linear alkyl group having 1 to 6 carbon atoms or a branched alkyl group such as tert-butyl, pentyl, hexyl and the like.
- Suitable "lower alkoxy groups” include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tertiary butoxy, pentyloxy, and hexyloxy groups. And the like, preferably those having 1 to 4 carbon atoms.
- lower alkenyloxy groups include preferably vinyloxy group, aryloxy group, 1-propenyloxy group, 1 (or 2) -butenyloxy group, 2-pentynyloxy group and the like. Those having 2 to 4 carbon atoms are exemplified.
- Suitable “amidated carboxy groups” include amides (1-CONH 2 ) which may have a suitable substituent on the nitrogen atom.
- appropriate substituents as described below Examples include a heterocyclic group which may be present, and an aryl group which may have an appropriate substituent.
- heterocyclic group refers to a saturated or unsaturated monocyclic group containing at least one heteroatom such as an oxygen, zeolite, nitrogen atom or the like.
- a cyclic or polycyclic heterocyclic group is meant.
- the preferred heterocyclic group may be, for example, the following heterocyclic group. That is:
- Unsaturated fused heterocyclic groups containing 1 to 4 nitrogen atoms such as indril, isoindolinol, indlizinyl, benzimidazolinol, quinolinolen , Isoquinoline, indazolyl, benzotriazolinole, tetrazolopyridyl, etc .: Unsaturated 3- to 8-membered, more preferably 5- or 6-membered heteromonocyclic group containing 1-2 oxygen atoms and 1-3 nitrogen atoms, e.g.
- oxazolyl isoxazolyl, oxaziazolyl (For example, 1,2,4—oxaziazolinole; 1,3,4-oxaziazolinole; 1,2,5—oxaziazolyl, etc.), etc .:
- Unsaturated fused heterocyclic groups containing 1-2 oxygen atoms and 1-3 nitrogen atoms such as benzoxazolyl, benzoxadiazolinol, etc .:
- Unsaturated condensed heterocyclic groups containing one to two zeo atoms and one to three nitrogen atoms such as benzothiazolyl, benzothiadiazolyl, and the like.
- An unsaturated condensed heterocyclic group containing one oxygen atom and one or two diatoms for example, a heterocyclic group such as benzoxathinyl and the like can be mentioned.
- the heterocyclic group may have one or more suitable substituents as described below. That is, lower alkyl (for example, methylol, ethyl, propyl, isopropyl, butyl, isobutyl, t-butynole, pentinole, neopentinole, hexinole, etc.), halogen (for example, chlorine, bromine, (Fluorine or iodine).
- lower alkyl for example, methylol, ethyl, propyl, isopropyl, butyl, isobutyl, t-butynole, pentinole, neopentinole, hexinole, etc.
- halogen for example, chlorine, bromine, (Fluorine or iodine).
- Suitable "aryl groups” include phenyl, tolyl, xylyl, cumenyl, naphthyl, biphenyl and the like, and these include amino, nitro, for example, chlorine. And a suitable group such as a halogen such as bromine, fluorine or iodine, or a group such as the above-mentioned lower alkoxy, carboxy, hydroxy, lower alkoxycarbonyl (eg, methoxycarbonyl, ethoxycarbonyl, etc.). It may have one or more substituents.
- a suitable group such as a halogen such as bromine, fluorine or iodine, or a group such as the above-mentioned lower alkoxy, carboxy, hydroxy, lower alkoxycarbonyl (eg, methoxycarbonyl, ethoxycarbonyl, etc.). It may have one or more substituents.
- Suitable "aryl groups” of "aryl thio group”, “ar (lower) alkyl group” and “aryl amino group” include those as exemplified above.
- alloyno group includes benzoyl, toluoyl, naphthoyl and the like.
- arenesulfonyl groups include benzenesulfonyl, P-tonolenesole and the like.
- the “aryl amino group” may have an appropriate substituent on the nitrogen atom, such as a lower alkyl group such as methyl and ethyl.
- aryloxy groups include phenoxy, trioxy and the like, and phenyl groups are particularly preferred.
- aminodated carboxy groups include pyruvamoyl, pyridylamide, pyrimidinylamide optionally having a lower alkyl group, villadinylamide, and hydroxy group.
- Suitable salts of the quinolizinone compound (I) include pharmaceutically acceptable salts, particularly commonly used non-toxic salts, and include salts with bases and acid addition salts, ie, inorganic bases. Salts such as alkali metal salts such as sodium salts and calcium salts, alkaline earth metal salts such as calcium salts and magnesium salts, ammonium salts, salts with organic bases, such as Triethylamine salt, pyridine salt, picolinate salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N, N, dibenzylamine Organic amine salts such as amine salts, inorganic acid addition salts such as hydrochloride, hydrobromide, sulfate and phosphate, formate, acetate, trifluoroacetate, maleine Acid salt, tartrate, methansulfonate, benzene Sulfo emissions salt, P - toluene organic carboxylic or sulpho phosphate addition salt
- quinolizinone compound (I) and salts thereof include monohydrate and tetrahydrate, with monohydrate being preferred.
- R ′ is a tetramer as an effective component of the preventive / therapeutic agent for interstitial pneumonia, inflammatory bowel disease or vascular hypertrophy of the present invention.
- a quinolizinone compound represented by a rubinoyl group, R 2 being hydrogen, R 3 being a phenoxy group, and R 4 being hydrogen, a salt thereof and a hydrate thereof are more preferred.
- the quinolidinone compound (I) and a salt thereof are produced by a known method.
- the production method is described in detail in Japanese Patent Application Laid-Open No. 60-222482.
- hydrates of the compound (III) represented by the above structural formula and a method for producing the same are described in detail in JP-A-1110473. Have been.
- the therapeutic agent is in the form of a pharmaceutical composition, for example, an organic or inorganic substance suitable for oral or parenteral administration of the active ingredient of the invention. It can be used in solid, semi-solid, or liquid form, containing it in admixture with a pharmaceutically acceptable carrier such as a solid or liquid excipient.
- a pharmaceutically acceptable carrier such as a solid or liquid excipient.
- the active ingredient may be mixed with conventional non-toxic pharmaceutically acceptable carriers, for example, for capsules, tablets, dragees, solutions, suspensions, emulsions or aerosols and other forms suitable for use. . Carriers that can be used are water, glucose,?
- the pharmaceutical composition may also contain a preservative or a bacteriostat to stably maintain the activity of the active ingredient in the desired preparation.
- the active quinolidinone compound (I) is contained in the pharmaceutical composition in an amount sufficient to exert the desired therapeutic effect according to the disease process and conditions.
- this pharmaceutical composition When this pharmaceutical composition is applied to humans, it is preferable to apply it by oral administration, inhalation administration, intravenous administration, intramuscular administration and the like.
- the dosage or therapeutically effective amount of the quinolizinone compound (I) should be Depending on the type and severity of the disease, the age and condition of each individual patient, the daily dosage for treatment of the disease in humans or animals is usually from about 0.1 to 10 mg of active ingredient. kg and is generally administered 1 to 3 times a day.
- test compound 1 [5- (1H—tetrazolinol)] 1-phenoxy-14H—quinolizine-14-one-3-3—Carboxamide sodium salt (hereinafter “test compound 1”) ")
- test Compound 2 [5- (1H—tetrazolinole)] 1- 1-phenoxy- 1 4H-quinolinidine- 1-one 3- 3-carboxamide sodium salt monohydrate (hereinafter referred to as “test Compound 2 ”)
- ICR mice (12-week-old, male) were injected intravenously with bleomycin (10 mg / kg) once a day for 10 days.
- Test Compound 1 was suspended in 0.5% methylcellulose and orally administered twice a day from the start of bleomycin administration to the day before dissection.
- the control group was treated with 0.5% methylcellulose and the test compound 1 administration group. Administered similarly.
- the group to which the physiological saline was intratracheally administered in the same manner was defined as a normal group.
- the drug was administered orally every day from the day of silica administration to the day before sacrifice, and test compound 1 and tranilast were administered once after silica administration and twice a day in the morning and evening from the next day. .
- the normal group and the control group received 0.5% methylcellulose in the same manner as the test compound 1 administration group.
- the male SD rats (7-8 weeks old) were fasted for 24 hours, and test compound 2 was suspended in 0.5% methylcellulose and orally administered.
- test compound 2 was suspended in 0.5% methylcellulose and orally administered.
- a 4% acetic acid-saline solution was injected from the anus into the lml Z-rat (the normal group was injected with saline). The injection was carried out for 20 seconds, and then maintained in an inverted position for 30 seconds, followed by injection of 2 ml of a phosphate buffer for washing.
- the animals were sacrificed by carbon dioxide inhalation, the large intestine was removed, and the state of lesion formation was scored to obtain the following lesion index.
- Table 3 shows the results. (Table 3)
- the quinolizinone compound (I), its salt and their hydrates are not suitable for various types of interstitial pneumonia [for example, Pulmonary disease (eg, pneumoconiosis, silicosis, asbestosis), irritable pneumonitis (eg, summer-type irritable pneumonia, farmer's lung), drug-induced pneumonia (eg, pneumonia due to side effects of bleomycin, etc.) ), Radiopneumonitis, infectious pulmonary disease (eg, miliary tuberculosis, mycoplasma pneumonia, etc.), pneumonia due to heart disease or malignant tumor, pulmonary fibrosis, collagenous interstitial pneumonia, psychodosis, For eosinophilic granulomatosis, alveolar proteinosis, pulmonary hemosis, goodpasture syndrome, etc. It is useful as a therapeutic agent.
- Pulmonary disease eg, pneumoconiosis, silicosis, asbestosis
- irritable pneumonitis eg
- the quinolizinone compound (I), a salt thereof and a hydrate thereof can be used for various inflammatory bowel diseases (eg, Crohn's disease, It is useful as a prophylactic and therapeutic agent for ulcerative colitis.
- the quinolizinone compound (I), its salts and their hydrates can be used for various angioplasty (eg, percutaneous coronary angioplasty), arterial bypass surgery, organ transplantation.
- angioplasty eg, percutaneous coronary angioplasty
- One tablet produced a tablet having the following composition.
- One tablet produced a tablet having the following composition.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96902481A EP0811378A1 (en) | 1995-02-23 | 1996-02-19 | Preventive/remedy for interstitial pneumonia, inflammatory intestinal diseases or vascular thickening containing quinolizinone compounds, salt thereof or hydrates therefor |
AU46770/96A AU4677096A (en) | 1995-02-23 | 1996-02-19 | Preventive/remedy for interstitial pneumonia, inflammatory intestinal diseases or vascular thickening containing quinolizinone compounds, salt thereof or hydrates therefor |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3566295 | 1995-02-23 | ||
JP7/35662 | 1995-02-23 | ||
JP28592595 | 1995-11-02 | ||
JP7/285925 | 1995-11-02 | ||
JP34151195 | 1995-12-27 | ||
JP7/341511 | 1995-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996025932A1 true WO1996025932A1 (fr) | 1996-08-29 |
Family
ID=27288833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/000371 WO1996025932A1 (fr) | 1995-02-23 | 1996-02-19 | Medicament preventif et curatif, pour la pneumonie interstitielle, les maladies inflammatoires intestinales ou l'epaississement des vaisseaux, contenant des composes de quinolizinone, des sels de ces composes ou des hydrates |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0811378A1 (ja) |
AU (1) | AU4677096A (ja) |
IL (1) | IL117155A0 (ja) |
WO (1) | WO1996025932A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025930A2 (en) * | 1996-12-13 | 1998-06-18 | F. Hoffmann-La Roche Ag | Use of bi- and tricyclic pyridone derivatives against alzheimer's disease |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200838534A (en) | 2007-02-07 | 2008-10-01 | Astellas Pharma Inc | Treatment for irritable bowel syndrome |
CN105001216B (zh) * | 2015-07-08 | 2017-03-01 | 中国科学院兰州化学物理研究所 | 一种喹嗪酮的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06256187A (ja) * | 1993-03-02 | 1994-09-13 | Fujisawa Pharmaceut Co Ltd | キノリジノン化合物またはその塩を含有する鎮咳・去痰剤 |
-
1996
- 1996-02-16 IL IL11715596A patent/IL117155A0/xx unknown
- 1996-02-19 AU AU46770/96A patent/AU4677096A/en not_active Abandoned
- 1996-02-19 WO PCT/JP1996/000371 patent/WO1996025932A1/ja not_active Application Discontinuation
- 1996-02-19 EP EP96902481A patent/EP0811378A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06256187A (ja) * | 1993-03-02 | 1994-09-13 | Fujisawa Pharmaceut Co Ltd | キノリジノン化合物またはその塩を含有する鎮咳・去痰剤 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025930A2 (en) * | 1996-12-13 | 1998-06-18 | F. Hoffmann-La Roche Ag | Use of bi- and tricyclic pyridone derivatives against alzheimer's disease |
WO1998025930A3 (en) * | 1996-12-13 | 1998-08-13 | Hoffmann La Roche | Use of bi- and tricyclic pyridone derivatives against alzheimer's disease |
US6030984A (en) * | 1996-12-13 | 2000-02-29 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
Also Published As
Publication number | Publication date |
---|---|
EP0811378A1 (en) | 1997-12-10 |
IL117155A0 (en) | 1996-06-18 |
AU4677096A (en) | 1996-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU199302B (en) | Process for producing synergic pharmaceutical compositions having hypotensive activity | |
NL8802059A (nl) | Esters en amiden van cyclische carbonzuren en cyclische alcoholen en aminen. | |
JP2002537258A5 (ja) | ||
WO1994012499A1 (en) | 1,8-naphthyridin-2-one derivative and use thereof_ | |
JPH0428269B2 (ja) | ||
WO2009129508A1 (en) | Soluble epoxide hydrolase inhibitors | |
JPH01254678A (ja) | ジヒドロピリジン化合物 | |
JPS58159489A (ja) | 2,3−ジアリ−ル−5−ハロチオフエン化合物 | |
WO1997026242A1 (fr) | Derives de 3-(bis-phenylmethylene substitue) oxindole | |
WO1996025932A1 (fr) | Medicament preventif et curatif, pour la pneumonie interstitielle, les maladies inflammatoires intestinales ou l'epaississement des vaisseaux, contenant des composes de quinolizinone, des sels de ces composes ou des hydrates | |
JP2005527518A (ja) | 新規なカルコン(chalcone)誘導体とその使用 | |
WO1994005290A1 (en) | Platelet aggregation inhibitor | |
JP3762799B2 (ja) | 抗不整脈剤及びその製法 | |
WO2016206576A1 (zh) | 一种氘代噻吩并哌啶衍生物、制备方法及其应用 | |
JPS61155327A (ja) | ジヒドロピリジン化合物を含有する抗動脈硬化剤 | |
JPS5944371A (ja) | 1―フエニル―2―メチル―3―(1―ピロリジニル)―1―プロパノン誘導体 | |
JPH0840934A (ja) | 利尿薬調製のためのニューロテンシン拮抗薬の使用およびニューロテンシン拮抗薬を含有する利尿薬組成物 | |
JPH0647540B2 (ja) | 虚血性心疾患・不整脈治療・予防剤 | |
JPS6339863A (ja) | 3−(ヒドロキシメチル)−イソキノリン誘導体およびその酸付加塩、その製造方法、並びにこれを含む薬剤組成物 | |
JPH0374329A (ja) | 胃炎治療剤 | |
WO2000068231A1 (fr) | Dihydrate derive de purine, medicaments le contenant comme principe actif et intermediaire utilise dans sa preparation | |
US3974164A (en) | Reserpic acid derivatives | |
US4678796A (en) | 2-alkylidene derivatives of 1,2,3,4-tetrahydropyridine-2,5-pyridine carboxylic acid dialkyl esters useful for treatment of cardiovascular disorders | |
JPH0578250A (ja) | 肝炎または膵炎の予防・治療剤 | |
KR20030002304A (ko) | 3-페닐-3,7-디아자비시클로[3.3.1]노난 화합물들과 이들의제조방법 및 이러한 화합물들을 포함하는 약제들 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN FI HU JP KR MX NO US AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996902481 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 894558 Date of ref document: 19970912 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996902481 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996902481 Country of ref document: EP |